Among 2238 Koreans with pre‐dialysis CKD, after a follow‐up of 3.5 years, serum adiponectin in the fourth quartile (16.80–79.88 μg/mL) was associated with a hazard ratio (HR) of 1.39 (95% CI 1.05–1.84) for a composite of kidney outcomes (defined as either a doubling of serum creatinine or the need for kidney replacement therapy), compared to those with serum adiponectin in the first quartile (≤5.09 μg/mL).17 This evidence concerns the gene ADIPOQ and chronic kidney disease.